Epigenomics AG (XETRA: ECX.DE) Stock Competitors & Peer Comparison
See ECX.DE's competitors and their performance on the XETRA and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ECX.DE and its XETRA peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ECX.DE | €0.70 | -11.17% | 612.6K | -0.04 | -€19.55 | N/A |
| TN8.DE | €597.40 | -2.19% | 220.9B | 33.36 | €17.91 | +0.27% |
| DAP.DE | €202.80 | -2.87% | 142.6B | 36.63 | €5.54 | +0.66% |
| ILU.DE | €124.28 | +0.60% | 18.8B | 29.38 | €4.23 | N/A |
| QIA.DE | €45.05 | +0.26% | 9.3B | 22.01 | €2.05 | +5.36% |
| SYAB.DE | €11.06 | -0.18% | 2.4B | 27.65 | €0.40 | +2.98% |
| MYD.DE | €26.72 | +0.00% | 2.2B | -256.92 | -€0.10 | N/A |
| NN6.DE | €1.60 | -2.74% | 22.2M | -10.67 | -€0.15 | N/A |
Stock Comparison
Thermo Fisher Scientific Inc. (XETRA: TN8.DE)
ECX.DE vs TN8.DE Comparison October 2026
Epigenomics AG (XETRA: ECX.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ECX.DE stands at 612.6K. In comparison, TN8.DE has a market cap of 220.9B. Regarding current trading prices, ECX.DE is priced at €0.70 on the XETRA, while TN8.DE trades at €597.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ECX.DE currently has a P/E ratio of -0.04, whereas TN8.DE's P/E ratio is 33.36. In terms of profitability, ECX.DE's ROE is -314.00%, compared to TN8.DE's ROE of +0.13%. Regarding short-term risk, ECX.DE is more volatile compared to TN8.DE. This indicates higher risk in terms of short-term price fluctuations for ECX.DE.Check TN8.DE's competition here